TITLE

Intracervical misoprostol and prostaglandin E2 for labor induction

AUTHOR(S)
Chang, Y.-K.; Chen, W.-H.; Yu, M.-H.; Liu, H.-S.
PUB. DATE
January 2003
SOURCE
International Journal of Gynecology & Obstetrics;Jan2003, Vol. 80 Issue 1, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objectives: To compare the safety and efficacy of misoprostol with PGE2 for induction of labor by intracervical administration. Methods: Eighty-six women with indications for labor induction at term were randomly assigned to two groups. Each woman received either 50 μg of misoprostol or 0.5 mg of prostaglandin E2 intracervically. If labor was not initiated after 4 h, the same dose was repeated every 4 h to a maximum of 200 μg of misoprostol or 1.5 mg of PGE2 until adequate labor was achieved. Results: Forty-three women were allocated to the misoprostol group and 43 to the prostaglandin E2 group. Misoprostol was more effective than PGE2 in producing cervical changes (P<0.025). Delivery within 12 h after the first administration occurred more often in the misoprostol group than in the PGE2 one (85% vs. 56%, P<0.05). Less patients in the misoprostol group required oxytocin augmentation than in the PGE2 one (16.3% vs. 39.5%, P<0.05). Uterine tachysystole and hyperstimulation occurred more frequently in the misoprostol group (44.1%) than in the PGE2 group (18.7%) (P<0.05). Nevertheless, no statistically significant differences were noted between the two groups including mode of delivery and neonatal or maternal adverse outcome. The interval from induction to vaginal delivery was significantly shorter in the misoprostol group (480±172 min vs. 657±436 min, P<0.01). Conclusions: Compared with prostaglandin E2, intracervical misoprostol is more effective in cervical ripening and labor induction at term. The higher frequency of uterine hypercontractility associated with the use of misoprostol did not increase the risk of adverse intrapartum and neonatal outcomes.
ACCESSION #
8902972

 

Related Articles

  • Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol Meydanli, M.M.; Çalışkan, E.; Burak, F.; Narin, M.A.; Atmaca, R.; Calişkan, E // International Journal of Gynecology & Obstetrics;Jun2003, Vol. 81 Issue 3, p249 

    Objectives: To compare the effectiveness of 25 μg vs. 50 μg of intravaginal misoprostol for cervical ripening and labor induction beyond 41 weeks’ gestation. Methods: The study population consisted of 120 women not in active labor with a gestational age >41 weeks, singleton...

  • Use of misoprostol on an outpatient basis for postdate pregnancy Kipikasa, J.H.; Adair, C.D.; Williamson, J.; Breen, J.M.; Medford, L.K.; Sanchez-Ramos, L. // International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p108 

    Objective: Within the obstetric community, several studies suggest that cervical ripening and labor induction after 40 weeks' gestation leads to improved maternal and neonatal outcomes. The most effective drug regimen to safely promote labor has not been determined.Method:...

  • A comparison of labor induction by oral and vaginal misoprostol Pongsatha, S.; Vijittrawiwat, A.; Tongsong, T. // International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p140 

    No abstract available.

  • Use of Oral Misoprostol for Cervical Priming before Hysteroscopy: A Randomized Comparison of Two Dosages. Kesrouani, Assaad; Maalouf, Samer; Mansour, Fersan; Attieh, Elie // Gynecologic & Obstetric Investigation;Jul2016, Vol. 81 Issue 4, p333 

    Objective: The study aims to compare the safety and effectiveness of 200 and 400 µg of oral misoprostol for cervical priming before hysteroscopy.Methods: A double-blinded randomized study included 70 patients scheduled for hysteroscopy in a Lebanese University...

  • Intravaginal and intracervical misoprostol for cervical ripening of labor in primiparas Ding, D.-C.; Su, H.-Y.; Chu, T.-W. // International Journal of Gynecology & Obstetrics;Aug2003, Vol. 82 Issue 2, p209 

    No abstract available.

  • Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Groopman, Jerome E.; Gottlieb, Michael S.; Goodman, Jesse; Mitsuyasu, Ronald T.; Conant, Marcus A.; Prince, Harry; Fahey, John L.; Derezin, Marvin; Weinstein, Wilfred M.; Casavante, Conrad; Rothman, John; Rudnick, Seth A.; Volberding, Paul A.; Groopman, J E; Gottlieb, M S; Goodman, J; Mitsuyasu, R T; Conant, M A; Prince, H; Fahey, J L // Annals of Internal Medicine;May84, Vol. 100 Issue 5, p671 

    In a randomized prospective study we tested the toxicity and efficacy of recombinant alpha-2 interferon in the treatment of Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. High doses (50 X 10(6) U/m2 body surface area, intravenously) or low doses (1 X 10(6) U/m2,...

  • Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Oehrberg, S.; Christiansen, P. E.; Behnke, K.; Borup, A. L.; Severin, B.; Soegaard, J.; Calberg, H.; Judge, R.; Ohrstrom, J. K.; Manniche, P. M. // British Journal of Psychiatry;Sep95, Vol. 167, p374 

    Background: This study compared the efficacy and tolerability of paroxetine with placebo in the treatment of panic disorder.Method: After three weeks of placebo, patients received 12 weeks of treatment with paroxetine (20, 40, or 60 mg) or placebo, and finally two weeks...

  • Cervical priming with sublingual misoprostol vs. 15-methyl-prostaglandin F2α prior to surgical abortion Vimala, N.; Mittal, S.; Dadhwal, V. // International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p134 

    Abstract: Objective: To compare the efficacy and tolerability of sublingual misoprostol with those of intramuscular 15-methyl-prostaglandin F2α (15-M-PG F2α) for cervical dilation prior to vacuum aspiration (VA) in first-trimester pregnancy termination. Methods: Sixty pregnant women...

  • Drug treatment of panic disorder. Reply to comment by Marks and associates. Klerman, Gerald L.; Klerman, G L // British Journal of Psychiatry;Oct92, Vol. 161, p465 

    A response by Gerald L. Klerman to a letter to the editor about his article on the summary report from the Second Phase of the Cross-National Collaborative Panic Study published in the February 1992 issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics